C. Askov-Hansen

Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

Karine Madsen, C. Askov-Hansen, Rahim M. Naimi et al. · Regulatory Peptides · 2013 · 88 citations

Short Bowel Syndrome, Medicine, Physiology +7

Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure

C. Askov-Hansen, Palle Bekker Jeppesen, P. Lund et al. · Regulatory Peptides · 2012 · 37 citations

Bone Health, Bone Resorption, High Concentration +9

Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients

Peter Høyerup, Per M. Hellström, P Schmidt et al. · Regulatory Peptides · 2012 · 35 citations

Physiology, Gastroenterology, Pathology +6

The use of metabolic balance studies in the objective discrimination between intestinal insufficiency and intestinal failure

August Pilegaard Prahm, Christopher F. Brandt, C. Askov-Hansen et al. · American Journal of Clinical Nutrition · 2017 · 14 citations

Obesity, Nutrition, Body Composition +12

A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

Rahim M. Naimi, Karine Madsen, C. Askov-Hansen et al. · Regulatory Peptides · 2013 · 11 citations

Gastrointestinal Peptide Hormone, Functional Gastrointestinal Disorder, Glp-2 Injections +7